Comparing AXIM Biotechnologies (OTCMKTS:AXIM) and Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals (NASDAQ:LXRX) and AXIM Biotechnologies (OTCMKTS:AXIM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.

Profitability

This table compares Lexicon Pharmaceuticals and AXIM Biotechnologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-8,311.12%	-108.54%	-61.97%
AXIM Biotechnologies	N/A	N/A	N/A

Earnings and Valuation

This table compares Lexicon Pharmaceuticals and AXIM Biotechnologies’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$2.31 million	188.68	-$177.12 million	($0.83)	-2.13
AXIM Biotechnologies	N/A	N/A	N/A	($0.01)	-1.41

AXIM Biotechnologies has lower revenue, but higher earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than AXIM Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Lexicon Pharmaceuticals and AXIM Biotechnologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	0	1	2	0	2.67
AXIM Biotechnologies	0	0	0	0	N/A

Lexicon Pharmaceuticals currently has a consensus target price of $5.00, indicating a potential upside of 182.49%. Given Lexicon Pharmaceuticals’ higher probable upside, equities research analysts clearly believe Lexicon Pharmaceuticals is more favorable than AXIM Biotechnologies.

Insider & Institutional Ownership

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 6.8% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

About AXIM Biotechnologies

AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases. The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests. It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.